Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

References

• Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 2012; 795:1 - 34; http://dx.doi.org/10.1007/978-1-61779-337-0_1; PMID: 21960212
   PubMedGoogle Scholar
• Natarajan N, Telang S, Miller D, Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 2011; 71:1233 - 50; http://dx.doi.org/10.2165/11591380-000000000-00000; PMID: 21770473
   PubMed Web of Science ®Google Scholar
• Montero JC, Seoane S, Ocaña A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011; 17:5546 - 52; http://dx.doi.org/10.1158/1078-0432.CCR-10-2616; PMID: 21670084
   PubMed Web of Science ®Google Scholar
• Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist 2011; 16:566 - 78; http://dx.doi.org/10.1634/theoncologist.2010-0408; PMID: 21521831
   PubMed Web of Science ®Google Scholar
• Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs 2010; 19:415 - 25; http://dx.doi.org/10.1517/13543781003592097; PMID: 20113198
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, Subramanian S, Devasahayam N, Munasinghe JP, Mitchell JB, et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011; 71:6350 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-11-2025; PMID: 21878530
   PubMed Web of Science ®Google Scholar
• Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, Spasojevic I, Dewhirst MW. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther 2010; 9:1798 - 808; http://dx.doi.org/10.1158/1535-7163.MCT-09-0856; PMID: 20515941
   PubMed Web of Science ®Google Scholar
• Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, McKenna WG, Bernhard EJ. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009; 69:6347 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-09-0657; PMID: 19622766
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148 - 57; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332; PMID: 19276286
   PubMed Web of Science ®Google Scholar
• Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011; 77:12 - 9; http://dx.doi.org/10.1016/j.critrevonc.2010.02.004; PMID: 20304669
   PubMed Web of Science ®Google Scholar
• Bose A, Lowe DB, Rao A, Storkus WJ. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 2012; 22:236 - 43; http://dx.doi.org/10.1097/CMR.0b013e3283538293; PMID: 22504156
   PubMed Web of Science ®Google Scholar
• Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011; 129:2158 - 70; http://dx.doi.org/10.1002/ijc.25863; PMID: 21170961
   PubMed Web of Science ®Google Scholar
• Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM, Chen SH. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111:219 - 28; http://dx.doi.org/10.1182/blood-2007-04-086835; PMID: 17885078
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69:2514 - 22; http://dx.doi.org/10.1158/0008-5472.CAN-08-4709; PMID: 19276342
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323; PMID: 19244102
   PubMed Web of Science ®Google Scholar
• Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, Gnoni A, Di Renzo N, Dammacco F, Tassone P, Ribatti D, et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008; 112:1346 - 56; http://dx.doi.org/10.1182/blood-2007-10-116590; PMID: 18524994
   PubMed Web of Science ®Google Scholar
• Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011; 117:2202 - 8; http://dx.doi.org/10.1002/cncr.25766; PMID: 21523734
   PubMed Web of Science ®Google Scholar
• Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, et al. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer 2012; 106:85 - 91; http://dx.doi.org/10.1038/bjc.2011.514; PMID: 22127285
   PubMed Web of Science ®Google Scholar
• Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010; 24:896 - 900; http://dx.doi.org/10.1038/leu.2010.11; PMID: 20147973
   PubMed Web of Science ®Google Scholar
• Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14:2484 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-07-4393; PMID: 18413841
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 2012; 120:4533 - 43; http://dx.doi.org/10.1182/blood-2012-02-407163; PMID: 22936666
   PubMed Web of Science ®Google Scholar
• Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85:387 - 98; http://dx.doi.org/10.1111/j.1600-0609.2010.01501.x; PMID: 20662899
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013; 27:914 - 24; http://dx.doi.org/10.1038/leu.2012.348; PMID: 23192016
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23:1398 - 405; http://dx.doi.org/10.1038/leu.2009.46; PMID: 19295545
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Götz M, Döhner H, Bunjes D, Schmitt M. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. Br J Haematol 2009; 144:195 - 205; http://dx.doi.org/10.1111/j.1365-2141.2008.07433.x; PMID: 19016717
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205:2125 - 38; http://dx.doi.org/10.1084/jem.20080099; PMID: 18725522
   PubMed Web of Science ®Google Scholar
• Yan M, Jene N, Byrne D, Millar EK, O’Toole SA, McNeil CM, Bates GJ, Harris AL, Banham AH, Sutherland RL, et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 2011; 13:R47; http://dx.doi.org/10.1186/bcr2869; PMID: 21521526
   PubMed Web of Science ®Google Scholar
• Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71:7463 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-11-2449; PMID: 22025564
   PubMed Web of Science ®Google Scholar
• Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A 2000; 97:5492 - 7; http://dx.doi.org/10.1073/pnas.090097697; PMID: 10779556
   PubMed Web of Science ®Google Scholar
• Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2004; 2:40; http://dx.doi.org/10.1186/1479-5876-2-40; PMID: 15563374
   PubMedGoogle Scholar
• Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 2007; 13:4233 - 44; http://dx.doi.org/10.1158/1078-0432.CCR-06-2981; PMID: 17634553
   PubMed Web of Science ®Google Scholar
• Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 2010; 70:9599 - 610; http://dx.doi.org/10.1158/0008-5472.CAN-10-1293; PMID: 21118964
   PubMed Web of Science ®Google Scholar
• Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, et al. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest 2012; 41:680 - 710; http://dx.doi.org/10.3109/08820139.2012.703745; PMID: 23017141
   PubMed Web of Science ®Google Scholar
• Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, Mami-Chouaib F, Chouaib S. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012; 72:4629 - 41; http://dx.doi.org/10.1158/0008-5472.CAN-12-1383; PMID: 22962263
   PubMed Web of Science ®Google Scholar
• Hasmim M, Noman MZ, Lauriol J, Benlalam H, Mallavialle A, Rosselli F, Mami-Chouaib F, Alcaide-Loridan C, Chouaib S. Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells. J Immunol 2011; 187:4031 - 9; http://dx.doi.org/10.4049/jimmunol.1101011; PMID: 21911602
   PubMed Web of Science ®Google Scholar
• Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F, et al. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 2011; 71:5976 - 86; http://dx.doi.org/10.1158/0008-5472.CAN-11-1094; PMID: 21810913
   PubMed Web of Science ®Google Scholar
• Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Suchorska WM, Jalil A, Lecluse Y, El Hage F, et al. The cooperative induction of hypoxia-inducible factor-1 α and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182:3510 - 21; http://dx.doi.org/10.4049/jimmunol.0800854; PMID: 19265129
   PubMed Web of Science ®Google Scholar
• Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008; 14:5947 - 52; http://dx.doi.org/10.1158/1078-0432.CCR-08-0229; PMID: 18829471
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006; 18:98 - 104; http://dx.doi.org/10.1016/j.coi.2005.11.013; PMID: 16343880
   PubMed Web of Science ®Google Scholar
• Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB, Goldbach C, Alber S, et al. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther 2011; 19:805 - 14; http://dx.doi.org/10.1038/mt.2010.295; PMID: 21189473
   PubMed Web of Science ®Google Scholar
• Wölfl M, Schwinn S, Yoo YE, Reß ML, Braun M, Chopra M, Schreiber SC, Ayala VI, Ohlen C, Eyrich M, et al. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis. Blood 2013; 122:1203 - 13; http://dx.doi.org/10.1182/blood-2013-03-488072; PMID: 23836556
   PubMed Web of Science ®Google Scholar
• Seliger B, Ritz U, Abele R, Bock M, Tampé R, Sutter G, Drexler I, Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61:8647 - 50; PMID: 11751378
   PubMed Web of Science ®Google Scholar
• Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162:989 - 94; PMID: 9916724
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252 - 64; http://dx.doi.org/10.1038/nrc3239; PMID: 22437870
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443 - 54; http://dx.doi.org/10.1056/NEJMoa1200690; PMID: 22658127
   PubMed Web of Science ®Google Scholar
• Shimokaze T, Mitsui T, Takeda H, Kawakami T, Arai T, Ito M, Iwaba A, Izumino H, Takahashi N, Kanno M, et al. Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Hematol Oncol 2009; 26:448 - 53; PMID: 19657995
   PubMed Web of Science ®Google Scholar
• Erkut M, Erkut N, Ersoz S, Arslan M, Sonmez M. A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use. Acta Haematol 2010; 123:205 - 6; http://dx.doi.org/10.1159/000306070; PMID: 20375493
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. BioDrugs 2011; 25:147 - 57; http://dx.doi.org/10.2165/11591840-000000000-00000; PMID: 21528941
   PubMed Web of Science ®Google Scholar
• Tinsley SM. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. J Clin Nurs 2010; 19:1207 - 18; http://dx.doi.org/10.1111/j.1365-2702.2009.03167.x; PMID: 20345830
   PubMed Web of Science ®Google Scholar
• Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs 2010; 19:415 - 25; http://dx.doi.org/10.1517/13543781003592097; PMID: 20113198
   PubMed Web of Science ®Google Scholar